ICTC Faculty
Didier Blaise
France
Bio
Didier Blaise
Prof Didier Blaise, MD: Aix Marseille Univ (AMU), Management Sport Cancer Lab (MSC EA4670) Institut Paoli Calmettes (IPC) Marseille, France
Didier Blaise, MD is professor of hematology at Aix Marseille University. He is director of the transplant and cellular immunotherapy program at Institut Paoli Calmettes, Marseille. He has contributed to more than 600 peer reviewed publications. His major focuses are optimization, social and economic evaluation of innovation in allogeneic transplantation.
Gabriel Brisou
France
Bio
Gabriel Brisou
I am a young MD-PhD in clinical onco-hematology actually working as a haematologist at Institut Paoli-Calmettes in Marseille France. My clinical work is turned toward the care of lymphoma patients. My scientific work is focused on the understanding of the complex biological mechanisms leading pre-tumoral B cells to follicular lymphoma.
Eolia Brissot
France
Bio
Eolia Brissot
Eolia Brissot, MD, PhD, is Associate- Professor of Hematology and works at Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France).. She then undertook a PhD at Sorbonne University in Paris, France, before working at the laboratory of hematologic stem cell transplantation unit at the National Institute of Health, Bethesda, USA. She is Secretary of the ALWP of the European Society for Blood and Marrow Transplantation (EBMT). She has a special clinical and research focus on the development of GVHD prophylaxis, immunotherapy and different aspects of therapy of acute lymphoblastic leukemia.
Antoine Capes
France
Bio
Antoine Capes
Graduated medical school in 2013 at ‘’Université Catholique de Lille’’ Lille, France.
Residency and fellowship in internal medicine and clinical hematology at Saint-Luc Clinics, Brussels, Belgium.
Worked in clinical hematology and cellular therapy at the Lille university hospital.
Currently working in the clinical hematology and cellular therapy department at the Saint-Antoine hospital, Paris, France.
Bhagirathbhai Dholaria
USA
Bio
Bhagirathbhai Dholaria
Dr. Dholaria is currently an associate professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid neoplasms, plasma cell malignancies, adoptive cellular therapies, and stem cell transplantation. He has conducted studies investigating the outcomes of patients with non- Hodgkin lymphoma and acute leukemia undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to address relapse after CAR T therapy in lymphoma and multiple myeloma.
Rémy Duléry
USA
Bio
Rémy Duléry
Dr. Remy Dulery is an onco-hematologist at Saint-Antoine Hospital, Sorbonne University, France. He received his medical degree from the University of Lille, France, and his PhD from Sorbonne University in Paris, France. Dr. Dulery specializes in hematopoietic cell transplantation and cellular therapy, with a particular expertise in caring for patients with lymphoma or myelofibrosis as well as in cardio-oncology. His research is dedicated to improving outcomes for all patients, with a special emphasis on those who are frail or have refractory disease. Dr. Dulery is committed to enhancing patients’ quality of life by mitigating the harmful effects of therapy-induced toxicities.
Jordan Gauthier
USA
Bio
Jordan Gauthier
Jordan Gauthier, MD, MSc, is an Associate Professor at the Fred Hutchinson Cancer Center (FHCC) and the University of Washington in Seattle, WA, and the Medical Director of the Fred Hutch Immunotherapy Long-Term-Follow-up Program. He was the first physician to be awarded the FHCC Immunotherapy Integrated Research Center Fellowship Award. An expert in the field of CAR T-cell therapy and hematopoietic cell transplantation, he has co-authored over 100 abstracts and publications in high-impact journals such as Blood, Blood Advances, The Lancet Haematology, and Nature Reviews Clinical Oncology. Dr. Gauthier was one of the first investigators to characterize the safety and efficacy of repeat CD19 CAR T-cell infusions and to investigate the concurrent use of ibrutinib with CD19 CAR T cells in patients with refractory CLL. He is the Principal Investigator of several investigator-initiated clinical trials at the FHCC aimed at preventing toxicities after CD19 CAR T-cell therapy using innovative strategies such as IL-1R blockade with anakinra, and endothelial protection with IFN-beta-1a treatment.
Yongxian Hu
China
Bio
Yongxian Hu
Hu Yongxian, MD/PhD, Chief physician in Bone Marrow Transpantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, China. She serves as the young Committee of Chinese Society of Hematology, Secretary of Chinese Anti-Cancer Association, Vice president of young Committee of Zhejiang Society of Immunology. She engaged in the clinical transformation of novel chimeric antigen receptor T cell (CAR-T) therapy. She developed novel CAR-T treatment strategies on refractory/refractory acute lymphoblastic leukemia, Lymphoma and multiple Myeloma. In the past 5 years, she published about 50 papers as the first or corresponding author in journals such as Nature, Lancet Hematology, Cell Research, Blood, Nature Communications, etc. She was invited to give 15 invited presentations and oral presentations at large international conferences. As a member of the expert group, she compiled 6 Chinese expert consensus of cellular immunotherapy. She also won the first prize of Zhejiang Science and Technology Progress Award as the second winner in 2020. The research results were selected as one of the top ten hematology Advances in China in 2022.
He Huang
China
Bio
He Huang
He Huang, M.D., Ph.D., is the Dean of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University, Hangzhou, China. Prof. Huang specializes in clinical and basic research on hematopoietic stem cell transplantation, cellular immunotherapy and stem cell biology research. As corresponding author, he has published 206 original papers in SCI-cited journals including top journals in the field of hematology. For his outstanding achievement on hematopoietic stem cell transplantation, Pro. Huang was awarded the national prizes twice in 2003 and 2015, respectively.
Florent Malard
France
Bio
Florent Malard
Florent Malard, MD, PhD, studied medicine at the University of Nantes, France and obtained his PhD degree at Sorbonne Université in Paris, France, followed by a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center, New York, USA. He is now appointed as a Professor of Hematology at Sorbonne Université and Saint-Antoine Hospital, Paris, France. His research works focused on allogeneic hematopoietic cell transplantation, immunology, microbiota and multiple myeloma. He has published so far over 100 publications on these topics.
Mohamad Mohty
France
Bio
Mohamad Mohty
Mohamad Mohty is full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France).
Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.
Professor Mohty is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents.
He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.
Professor Mohty serves on the board of the European Society for Blood and Marrow Transplantation (EBMT), and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, International Society for Experimental Hematology, and EBMT.
Professor Mohty has published more than 430 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals.
He also serves as Editor-in-Chief of the journal Bone Marrow Transplantation, as Associate Editor for Leukemia, European Journal of Haematology and Blood Cancer Journal, as member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as Blood, The Lancet, and Nature Reviews.
Arnon Nagler
Israel
Bio
Arnon Nagler
Professor Arnon Nagler, MD, MSc
Chaim Sheba Medical Center, Israel
- Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
- Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
- Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
- One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
- Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
- Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
- Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
- Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
- Chair of the Acute Leukemia Working Party (ALWP) of the EBMT
Dr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.
Dr Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Rizwan Romee
USA
Bio
Rizwan Romee
Dr. Rizwan Romee is an associate professor of medicine at Harvard Medical School and an oncologist at Dana Farber Cancer Institute (DFCI), Boston. He is also the principal investigator of the Romee Lab for NK Cell Gene Manipulation and Therapy (https://romeelab.dana-farber.org) at DFCI. The research focus of his laboratory is gene manipulation of the NK cells and other immune cells to enhance their anti-tumor function and simultaneously modulate the highly immune suppressive tumor microenvironment (TME). Dr. Romee also leads several early-phase clinical trials combining memory-like NK cells with various immunomodulatory agents in advanced liquid and solid malignancies.
Marion Subklewe
Germany
Bio
Marion Subklewe
Marion Subklewe is Professor of Internal Medicine with focus on Cellular Immunotherapy within the medical department for hematology / oncology at the LMU – University Hospital Munich. She is Head of the immunotherapy program in hematology and the CAR T program at the University Hospital Munich, leading an intermediate care unit and an early clinical trial unit as well as a large outpatient clinic for pts with acute leukemias and aggressive lymphomas. She is heading the lab for Translational Cancer Immunotherapy at the Gene Center Munich with focus on translational research in t cell based immunotherapy. Her research is focused on understanding mode of action and mode of resistance of bispecific and bifunctional antibody constructs. Current research integrates an adapter CAR T cell platform and combinatorial approaches in the setting of AML. She is speaker of the national “Harmonize MRD Flow” consortium and member of the ELN working group on MRD. She is Principal Investigator in I-IT trials in AML and ALL as well as in > 30 oligo – and multicentric C-IT trials in leukemias and lymphoma.
Alvaro Urbano-Ispizua
Spain
Alvaro Urbano-Ispizua
Dongrui Wang
China
Bio
Dongrui Wang
Dongrui Wang, PhD, is a principal investigator at Zhejiang University. Dr. Wang received his PhD from City of Hope Medical Center, and postdoctoral fellowship at the University of Texas MD Anderson Cancer Center. His research is focused on the development and refinement of cellular therapy targeting hematological malignancies and solid tumors, and his contributions set the fundaments of several clinical studies.
Yishan Ye
China
Bio
Yishan Ye
Dr. Yishan Ye is the special invited associate research fellow and attending physician at the First Affiliated Hospital, Zhejiang University School of Medicine, and is the young Ambassador of the International Academy of Clinical Hematology (IACH). Dr. Ye obtained doctorate from the Sorbonne University under the mentorship of Professor Mohamad Mohty.
As the first author/corresponding author, Dr. Ye has published over 10 papers in SCI cited journals including the Journal of Hematology & Oncology, and serves as a guest reviewer for journals including Bone Marrow Transplantation. He has presented orally three times at the American Society of Hematology (ASH) Annual Meeting and several times at the Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). Meanwhile, he has received twice the Best Yound Oral Abstract Award of EBMT.
Jin Zhang
China
Bio
Jin Zhang
Jin Zhang is a professor at Zhejiang University School of Medicine. He graduated at UCLA with a PhD degree in Cellular and Molecular Pathology, and did his postdoc at Boston Children’s Hospital/Harvard Medical School. His research focues on development, reprogramming and iPSC-derived immune cells for new cancer immunotherapies.
Mingming Zhang
China
Bio
Mingming Zhang
Mingming Zhang is an Associate Chief Physician from Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang University School of Medicine. He focused on Cellular immunotherapy for hematological malignancies and had published a series of articles in high level journals, including Lancet haematology, Clinical cancer research, and American journal of hematology.